EUROFINS SCIENT (ERFSF)
(Delayed Data from OTC)
$73.90 USD
+1.40 (1.94%)
Updated Sep 19, 2025 03:51 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ERFSF 73.90 +1.40(1.94%)
Will ERFSF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ERFSF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ERFSF
EUROFINS SCIENT (ERFSF) Upgraded to Buy: What Does It Mean for the Stock?
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year?
ERFSF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year?
EUROFINS SCIENT (ERFSF) Upgraded to Strong Buy: Here's Why
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year?
Other News for ERFSF
Eurofins Scientific price target raised by EUR 2 at Morgan Stanley
Tracking Ruane, Cunniff, & Goldfarb's Portfolio - Q2 2025 Update
What Worked In Q2: Longleaf's Most Impactful Global Holdings
Eurofins Scientific price target raised by EUR 8 at Berenberg
Eurofins Scientific price target raised by EUR 10.40 at Citi